New Release of Genedata Expressionist Expands GxP Compliance Support for Late-Stage Biotherapeutics Development
Genedata Expressionist 17.0 augments functionalities facilitating implementation of mass spectrometry-based analytical processes in regulated environments
Basel, Switzerland—Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the latest release of Genedata Expressionist®, its platform for streamlining and automating mass spectrometry data workflows, from early discovery to late-stage development of biopharmaceuticals. Building on a comprehensive enterprise platform, Genedata Expressionist 17.0 dramatically accelerates MS-based analytical processes and facilitates their implementation in regulated environments by introducing advanced functionalities that set new standards for automated data processing and data integrity.Developed in close collaboration with leading biopharma companies, this release offers new user-friendly commenting functionalities that simplify the systematic recording, reporting, and auditing of user interventions during data processing and result review. The platform integrates seamlessly with corporate IT infrastructures and streamlines data governance processes by creating archivable, permanent, and immutable project records that guarantee full data integrity and traceability of all data processing steps throughout the analysis. Given the ever-growing volume and complexity of MS data generated during analyses, Genedata Expressionist is continuously developed to provide novel functionalities that expedite highly automated data processing workflows in the biopharma industry. In this release, enhanced metadata management streamlines fully automated data processing of large sample batches. By automatically extracting sample-specific information—such as the protein sequence—from metadata, Genedata Expressionist 17.0 enables accelerated end-to-end automation of batch data processing, with each round being specifically tailored to the sample: boosting analytical throughput while simultaneously improving result quality. “This release further cements the position of Genedata Expressionist as the industry-leading enterprise platform for the end-to-end automation of MS data analysis” stated Othmar Pfannes, Ph.D., CEO of Genedata. “By facilitating regulatory compliance and accelerating workflow automation, Genedata Expressionist 17.0 represents an important milestone on the journey of biopharma toward rapid and cost-effective development of next-generation therapies.”
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
[www.genedata.com]www.genedata.comLinkedIn | Twitter | YouTubeContact
Allison Kurz[email protected]Genedata Public Relations
The statements in this press release to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the company’s products and services. Readers are cautioned not to place undue reliance to forward-looking statements, which speak only as the date hereof. The Company undertakes no obligation to release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after date hereof or to reflect the occurrence of unanticipated events.All Products and service names mentioned are trademarks of their respective companies.